Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $24,365 | $37,879 |
| General and administrative | 20,975 | 6,568 |
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s R&D?
- Mineralys Therapeutics, Inc. (MLYS) reported R&D of $24.37M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s R&D changed year-over-year?
- Mineralys Therapeutics, Inc.'s R&D decreased by 35.7% year-over-year, from $37.88M to $24.37M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s R&D?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s R&D has grown at a 71.3% compound annual growth rate (CAGR), from $26.25M to $132.01M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Mineralys Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude